HC Wainwright Reaffirms “Buy” Rating for Genfit (NASDAQ:GNFT)

HC Wainwright reaffirmed their buy rating on shares of Genfit (NASDAQ:GNFT) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $13.00 target price on the stock.

Genfit Stock Performance

Shares of NASDAQ GNFT opened at $4.84 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.94 and a current ratio of 2.94. Genfit has a 52-week low of $2.89 and a 52-week high of $6.05. The company’s 50 day moving average price is $4.23 and its 200-day moving average price is $4.06.

Hedge Funds Weigh In On Genfit

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. boosted its stake in Genfit S.A. (NASDAQ:GNFT) by 2,229.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,359 shares of the company’s stock after purchasing an additional 78,823 shares during the quarter. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.